Last reviewed 2026-04-20 · How we verify

Ids-Ne-007 (ETORPHINE)

Etorphine (Ids-Ne-007) is a potent opioid analgesic currently on the market, with a key composition patent expiring in 2028. Its primary strength lies in its high efficacy in pain management due to its strong binding to opioid receptors. The primary risk is the competitive landscape, particularly from off-patent drugs like alfentanil and patent-protected competitors such as alvimopan and amiodarone.

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Hyperthermia
• Muscle tremors
• Increased muscle tone
• Passive regurgitation of rumen contents
• Excitement
• Tachycardia
• Hypertension

Serious adverse events

• Respiratory depression
• Hypoventilation
• Hypoxaemia
• Metabolic acidosis
• Bradycardia
• Aspiration pneumonia
• Severe alkalosis
• Hyper-excitability
• Hyperventilation
• Depressed oxygen uptake in newborn

Key clinical trials

• Long-term Opioid Therapy, Misuse and Mortality in Patients With Chronic Non-cancer Pain in Germany

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Ids-Ne-007 CI brief — competitive landscape report
• Ids-Ne-007 updates RSS · CI watch RSS